A pair of new studies finds no significant benefit of the antiviral drug nirmatrelvir-ritonavir (Paxlovid) in alleviating the symptoms of adult long-COVID patients or in preventing the development of the condition in adolescents.
The Department of Health and Human Services has abruptly canceled more than $12 billion in federal grants to states that were being used for tracking infectious diseases, mental health services, addiction treatment and other urgent health issues.
COVID-19 vaccination slashed the risk of experiencing prolonged symptoms by about 27% in fully vaccinated adults who were later infected, estimates a European Centre for Disease Prevention and Control (ECDC) systematic review of 12 studies.
Recent Comments